US UK Tax Returns Preparation for Biotech Founders
By US-UK Tax Advisors cross-border tax team · Last updated OCT 30, 2026

One funding round can change a biotech founder's CFC, PFIC and BADR position at once. How we prepare both countries' returns from spin-out to final milestone.
Key Takeaways
- Covers cross-border tax for US-UK cross-border taxpayers
- Applies to US persons with UK ties and UK residents with US income
- Highlights the filing, reporting and tax-treaty points to check
- Get personalised advice before acting on your own facts
US UK tax returns preparation for a US-citizen scientist who founds a UK biotech spin-out means filing in both countries every year, even while the company has no revenue and the shares look worthless on paper. The filings that matter most are the 30-day section 83(b) election, Form 5471 or Form 8621 on the UK company, and the UK Self Assessment return, followed by a sale that is taxed under two systems that do not recognise each other's reliefs.
The failure mode we see most often is a filing position set in year one and copied forward after a funding round has changed the facts. One priced round can end controlled foreign corporation status, move a founder into the passive foreign investment company rules, and thin a holding towards the 5% floor for Business Asset Disposal Relief. We treat each round as a re-test date, and this article is built around that discipline.
What does US UK tax returns preparation involve for a biotech founder?
A US citizen resident in the UK files a UK Self Assessment return and a US Form 1040 for the same income, on different tax years, with relief for double taxation claimed mainly on the US side. A long-running pre-revenue company adds entity-level reporting that an employee of a large group never sees. The recurring items in the returns we prepare for spin-out founders are:
- Form 1040 with Form 2555 or Form 1116 for salary, and Form 1116 again for UK capital gains tax on an exit
- Form 5471 if the founder meets a filing category for the UK company, even in a year of pure losses
- Form 8621 where the company is a PFIC for that shareholder and no CFC overlap applies
- FBAR and Form 8938 where account and asset thresholds are met, including accounts a founder can sign on as a director
- The UK return, with employment income, share scheme events and the capital gains pages
- One-off elections with short clocks, chiefly section 83(b) on the US side and the joint restricted securities election on the UK side
Should a founder file a section 83(b) election on nominal-value shares?
Where founder shares are subject to vesting or another substantial risk of forfeiture, the answer is almost always yes. Section 83(a) taxes the excess of value over price paid when the restriction lapses, which for a successful company could mean ordinary income on a large value in a year when nothing has been sold. Section 83(b) moves that measurement to the transfer date, when the value may be close to the nominal price paid. The statute at https://www.law.cornell.edu/uscode/text/26/83 sets the deadline at no later than 30 days after the transfer, allows revocation only with the Secretary's consent, and denies any deduction if the shares are later forfeited.
Three spin-out details catch people. First, the clock runs from the transfer, and UK corporate counsel are rarely thinking about a US election, so we ask founders to tell us about any share issue before it happens. Second, nominal value and fair market value differ. If shares are issued after the intellectual property licence is agreed, or just before a priced round, the election may report compensation income, so the cleanest sequence is to issue founder shares early. Third, reverse vesting is often added at seed stage. Adding restrictions to shares already owned outright is generally not a fresh transfer, but a share exchange or new holding company can be one.
The UK has a parallel but separate concept: a joint election between employer and employee under the employment-related securities rules, with its own time limit. Neither election works for the other country, and both filed copies belong in the permanent file, because a buyer's diligence team will ask for them.
How are UK EMI options treated on a US tax return?
Enterprise Management Incentive options are a UK-only status. The GOV.UK summary at https://www.gov.uk/tax-employee-share-schemes/enterprise-management-incentives-emis lists the current conditions: company gross assets of £120 million or less (the earlier limit of £30 million applied on or before 5 April 2026), fewer than 500 full-time employees (previously 250), options worth up to £250,000 in a 3-year period, and a working time test of at least 25 hours a week or 75% of total working time. Exercise at no less than the market value at grant means no UK Income Tax or National Insurance, leaving Capital Gains Tax on the sale. Founders with a large holding should also check the material interest restriction, which can shut them out of EMI altogether.
The US does not recognise any of that. An EMI option is generally a nonstatutory option on the US return, so the spread at exercise is ordinary compensation income. That produces a mismatch: US tax at exercise with no UK tax to credit, then UK Capital Gains Tax on sale with little remaining US gain to set it against, because the US basis stepped up at exercise. Exercising only on the sale itself compresses the two events into one year and usually narrows the problem.
Options also count for US purposes: they can feed into Form 5471 category tests through attribution, and the PFIC rules can reach an option holder, as the CFC overlap rule at https://www.law.cornell.edu/uscode/text/26/1297 shows.
Is Form 5471 required when the UK company is loss-making?
Yes. Form 5471 is triggered by ownership and office, not by profit, and losses do not switch it off. The IRS instructions at https://www.irs.gov/instructions/i5471 describe the categories that matter here. Category 2 covers a US citizen or resident who is an officer or director of a foreign corporation in which a US person acquires stock meeting the 10% threshold. Category 3 covers a US person who acquires stock that reaches that 10% threshold by vote or value. Category 4 covers a US person with more than 50% of the vote or value. Category 5a covers a US shareholder owning 10% or more of a CFC, which is a foreign corporation more than 50% owned by US shareholders.
A CFC is therefore a test of the US shareholder group. Two US scientists holding 35% and 25% make the company a CFC, while a single US founder holding 40% alongside non-US co-founders and investors does not.
The penalty does not scale with results. The instructions set $10,000 per annual accounting period for each foreign corporation, a further $10,000 for each 30-day period if the failure continues beyond 90 days after IRS notice, up to a $50,000 maximum, and a possible 10% reduction in foreign taxes available for credit. A founder who has never filed, and whose omissions were non-willful, should look at the Streamlined Filing Compliance Procedures before the next round brings outside scrutiny.
The harder point sits inside the form. Schedule I-1 and Schedule Q are prepared on US tax principles, not from the UK accounts. US rules generally require research spending carried on abroad to be capitalised and amortised over a long period. A company reporting a heavy UK loss can therefore show far less of a loss on the US computation, and in some years positive income, especially if it also earns interest on round proceeds. For a CFC shareholder that can mean a section 951A inclusion on a company that has never made a profit. We build the US computation from the first year, because reconstructing years of research spend at exit is slow and expensive.
How does the US side see UK R&D tax credit receipts?
UK research relief now runs mainly through the merged R&D expenditure credit scheme and enhanced R&D intensive support for loss-making intensive small companies. In either case, cash can reach a loss-making company from HMRC. We could not find published IRS guidance that addresses these specific UK payments, so what follows is how we approach them, not a settled rule.
The credit belongs to the company, so nothing appears directly on the Form 1040. Its relevance is at the company computation on Form 5471 and in the PFIC test. UK accounts may present the receipt as other income or within the tax line, and neither presentation decides the US character. The arguable readings are a refund of foreign tax, or a government payment that is income. If it is income, it is hard to see it as passive, which would help the 75% test. We document the reading chosen, apply it consistently, and do not rely on the credit to rescue a PFIC conclusion.
Can a pre-revenue biotech company be a PFIC?
Yes, and a pre-revenue company is more exposed than an operating one. A PFIC is a foreign corporation where 75% or more of gross income is passive, or where at least 50% of assets on average produce passive income or are held to do so, under https://www.law.cornell.edu/uscode/text/26/1297. A company with no product sales and a bank balance from a funding round can have interest as its only gross income, which makes passive income 100% of the total however much science is being done. Research spending does not create gross income. Long-standing IRS guidance also treats cash as a passive asset, even when it is earmarked for trials.
The start-up exception at https://www.law.cornell.edu/uscode/text/26/1298 is narrower than founders are told. Section 1298(b)(2) removes PFIC status only for the first taxable year the corporation has gross income, and only if no predecessor was a PFIC, it is established to the Secretary's satisfaction that the company will not be a PFIC in either of the next two years, and it in fact is not. Interest in year one starts the clock, and interest is likely to be the only gross income in years two and three as well. A company with a licensing deal close behind may fit. A company years from revenue usually does not.
The CFC overlap in section 1297(d) is the main protection. A corporation is not treated as a PFIC for a shareholder during the part of the holding period in which that person is a US shareholder of a CFC. It protects 10% holders only, and only while the company is a CFC. When a round takes US ownership to 50% or below, protection ends and a new PFIC holding period generally begins for that founder. A US holder below 10% never had it. The asset test also changes basis: a non-traded CFC measures assets by adjusted basis, while a non-CFC generally measures by value, unless it elects otherwise.
The cost of getting this wrong falls at exit. Without an election, gain on PFIC shares is treated as an excess distribution, allocated across the holding period and taxed at top ordinary rates with an interest charge. A qualified electing fund election on Form 8621 is the usual cure, and for a loss-making company it is cheap, because the holder is taxed on a share of earnings the company does not have. The price is an annual information statement from the company, so we ask founders to write that statement into the investment agreement at the round.
Why does a funding round force a re-test?
This is the angle we rarely see addressed: the same round moves all of these tests in one transaction. We run the following decision list on every closing.
- If US shareholders of 10% or more together fall to 50% or below, then CFC status ends on that date: stop assuming section 1297(d) protection and make a QEF decision for the current year
- If the founder's stake crosses 10% in either direction, then check for a new Category 3 event or a change in Form 5471 schedules
- If new preference shares rank ahead of ordinary shares, then model the founder's share of sale proceeds against the 5% test, not just the percentage on the cap table
- If the balance sheet is now mostly cash, then recheck the PFIC asset test and whether surplus cash threatens UK trading company status
- If new options are granted, then recheck EMI limits at grant and include the options in US ownership counts
- If shares are exchanged for a new holding company, then treat this as a possible new transfer with a new 30-day clock and a fresh review of the PFIC predecessor condition
- If the founder has stepped back from a company role, then count how far the two-year officer or employee period for BADR has run
Can a US founder claim QSBS on a UK company?
No. Section 1202 limits a qualified small business to a domestic C corporation, as the text at https://www.law.cornell.edu/uscode/text/26/1202 states, so shares in a UK company do not qualify however closely the business matches the policy. This surprises founders who have heard US colleagues describe a large federal exclusion on exit.
A later flip to a US parent does not retrieve the past. Only stock acquired at original issue from a qualifying domestic corporation counts, and the gross assets test, now $75,000,000 for stock issued after July 4, 2025, can fail at the moment of the flip. For stock acquired after that date, the exclusion is tiered at 50% after 3 years, 75% after 4 and 100% after 5.
How does Business Asset Disposal Relief interact with US gain on exit?
BADR is a UK relief that reduces the UK rate on qualifying gains up to a lifetime limit. HMRC's helpsheet at https://www.gov.uk/government/publications/entrepreneurs-relief-hs275-self-assessment-helpsheet/hs275-business-asset-disposal-relief-2026 gives a rate of 18% for disposals on or after 6 April 2026, a cumulative lifetime limit of £1 million, and a claim deadline of the first anniversary of the 31 January following the tax year of disposal. Gains above the limit are taxed at the normal rate. Budget 2026 then moved the goalposts: the measure at https://www.gov.uk/government/publications/capital-gains-tax-reduction-in-the-business-asset-disposal-relief-lifetime-limit/capital-gains-tax-new-business-asset-disposal-relief-lifetime-limit proposes cutting the lifetime limit to £500,000 for qualifying disposals on or after 6 April 2027, with anti-forestalling rules for unconditional contracts not completed by then. It is due in the Finance Bill 2026, so check the enacted wording for the actual disposal date. The same Budget proposes a Founders' Relief at https://www.gov.uk/government/publications/capital-gains-tax-introduction-of-a-founder-relief/capital-gains-tax-introduction-of-a-new-founders-relief: a 10% rate on up to £10 million of lifetime gains from 6 April 2027. The conditions include holding 25% of the ordinary shares when the trade or its preparation began, five tax years of holding and of UK residence, and turnover of at least £10 million with at least 15 qualifying full-time equivalent employees. A pre-revenue biotech will usually fail the turnover test, and any US citizen who does qualify would have a thinner UK credit against US tax at 10%.
The personal company conditions run for the two years ending on disposal: a trading company, an officer or employee role, and at least 5% of ordinary share capital and votes, plus 5% of distributable profits and assets on a winding up and 5% of sale proceeds. Preference stacks can push the proceeds entitlement below 5% even when the cap table shows more. A scientist who returned full time to a research post may have dropped the officer or employee role. Large cash reserves may invite a question about trading status. EMI shares can qualify even where the personal company requirement is not met.
The US has no equivalent, so the relief can leak. If the UK rate on the gain falls below the US rate, the difference goes to the US Treasury. The gain must also be foreign source, or re-sourced under the treaty, to support the credit. The Net Investment Income Tax generally cannot be reduced by foreign tax credits, so a residual US charge can remain even if UK tax is higher overall.
How do milestone and earn-out payments get taxed?
Biotech sales often pay part of the price on trial results or regulatory approval, sometimes years later. In the UK, a right to an unquantified future payment is generally treated as a separate asset, valued and taxed at completion, with later receipts producing a further gain or loss on that right. Those later gains may not attract BADR, and the helpsheet does not address earn-outs, so we consider each agreement on its terms.
On the US side, contingent payments are commonly reported on the installment method, with part of each receipt recharacterised as interest. So the UK may tax value at completion while the US taxes cash years later, and foreign tax credits have limited carryback and carryforward periods that a long milestone schedule can outrun. Any payment conditional on the founder continuing to work is at risk of being employment income in both countries, which is why we read the sale agreement before signature.
What does a founder timeline look like? A worked example
This scenario is an illustration only. All names and figures are invented, and it assumes an exchange rate of $1.30 to £1. It also assumes a 24% UK main capital gains rate and US rates of 20% on long-term gain and 3.8% for Net Investment Income Tax, each adopted for this illustration only and to be confirmed for the actual year.
Dr A, a US citizen living in the UK, co-founds a spin-out in Year 1, paying £350 for 35% of the shares with vesting, and files a section 83(b) election within 30 days. A second US founder holds 25%, a non-US founder 20%, and a research institution 20%. US shareholders together hold 60%, so the company is a CFC. In Year 3, a £4 million seed round from non-US investors dilutes the two US founders to 26% and 19%, a combined 45%. CFC status ends that year, even though no one thinks of a seed round as a tax event. Dr A makes a QEF election for Year 3 and the company agrees to supply annual statements. Its only gross income is about £40,000 of interest, so it is a PFIC under the income test, with no ordinary earnings to pass through.
By Year 8, after further rounds, Dr A holds 9% of the ordinary shares, sitting behind £50 million of investor preference. In Year 9 the company is sold for £120 million upfront, plus milestones of up to £60 million. After preferences, £70 million reaches the ordinary shares, and Dr A receives £6.3 million, which is 5.25% of the upfront price. That passes the 5% proceeds test, but only narrowly, and only because we modelled the waterfall and not just the cap table.
- UK tax at BADR rate: £1,000,000 at 18% is £180,000 (the limit for a disposal before 6 April 2027; at the proposed £500,000 limit, UK tax rises by £30,000)
- UK tax at the assumed main rate: £5,300,000 at 24% is £1,272,000
- Total UK tax: £1,452,000, or about 23% of the gain, which is $1,887,600 at the assumed rate
- US gain: $8,190,000, with base cost ignored as trivial
- Assumed US tax at 20%: $1,638,000, fully covered by the UK credit if the gain is foreign source or re-sourced, leaving excess credit
- Assumed Net Investment Income Tax at 3.8%: $311,220, generally not reducible by the credit
- Dr A's share of milestones, up to £5.4 million, is handled separately under the timing rules above
The example shows two things. Without the QEF election, the same gain would be largely excess distribution income at top ordinary rates with interest. And the BADR saving of £60,000 survives here only because the rest of the gain carries enough UK tax to cover the US liability. Had the entire gain been within the £1 million limit, the 18% UK charge would have fallen short of the assumed 20% US rate, and the US would have collected the difference.
What gets filed in each year of a spin-out?
The list below is the year-by-year filing table for Dr A's timeline, in the form of a schedule we work to. Exact items depend on ownership and thresholds in each year.
- Year 1, incorporation: section 83(b) election within 30 days; UK joint election where relevant; Form 5471 (Categories 2, 3 and 5a); FBAR if signature authority and thresholds apply; UK return
- Year 2, research under way: Form 5471 with Schedules I-1 and Q on US principles, recording capitalised research costs; Form 1040 with Form 2555 or Form 1116; UK return
- Year 3, seed round: final CFC-period Form 5471, plus any new category events; first Form 8621 with QEF election; review of the start-up exception; UK return
- Years 4 to 7, further rounds: Form 8621 annually with company statements; Form 5471 where a category still applies, such as an officer or director event on a new 10% acquisition; re-test list at every closing; Form 8938 and FBAR as applicable; UK returns including any EMI grant records
- Year 8, pre-sale: EMI exercise planning, waterfall modelling for the 5% test, confirmation of the two-year officer or employee period, gathering of all prior elections
- Year 9, sale: UK return with capital gains pages and BADR claim within the time limit; Form 1040 with Form 8949, Schedule D, Form 1116, Form 8960 and final Form 8621; valuation of any earn-out right for the UK computation
- Years 10 and later, milestones: UK computation of gain or loss on each receipt; US installment reporting with imputed interest; tracking of unused foreign tax credits against their expiry
Our work is to prepare each country's returns from one continuous record of ownership, cash balances, research spending and role changes, so that the position taken at incorporation can be defended when a buyer, HMRC or the IRS finally reads it.
Related reading and tools
- US Tax Services & IRS Compliance
- UK Tax Services
- IRS Streamlined Filing
- UK Income Tax Calculator
- US Federal Income Tax Calculator
Every situation is different. Book a cross-border tax consultation to discuss how these rules apply to you.
Authoritative sources
IRS — Streamlined Filing Compliance Procedures
FinCEN — Report of Foreign Bank and Financial Accounts (FBAR)
GOV.UK — Tax on foreign income
IRS — Foreign Earned Income Exclusion



